We are live on ! Find out more
KTTA icon

Pasithea Therapeutics

26 hedge funds and large institutions have $16.7M invested in Pasithea Therapeutics in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,680% more capital invested

Capital invested by funds: $441K → $16.7M (+$16.2M)

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

49.48% more ownership

Funds ownership: 8.23%57.71% (+49%)

37% more funds holding

Funds holding: 1926 (+7)

Holders
26
Holders Change
+7
Holders Change %
+36.84%
% of All Funds
0.32%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
12
Increased
7
Reduced
3
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
-$22.5K -30,700 Closed
VF
27
Virtu Financial
New York
-$18K -25,075 Closed
TSS
28
Two Sigma Securities
New York
-$15.3K -20,846 Closed
HF
29
HRT Financial
New York
-$7K -10,896 Closed
Citigroup
30
Citigroup
New York
-$319 -443 Closed

KTTA Hedge Fund Activity: Q4 2025 in Review

26 of the 8,243 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q4 2025, worth a combined $16.7M — up 3,680% from $441K a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new KTTA positions and 5 closed out — a net gain of 7 holders — while 7 added to existing stakes and 3 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $1.85M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $22.5K sold.

  • 26 institutional investors held Pasithea Therapeutics (KTTA) as of Q4 2025, up from 19 in Q3 2025.
  • Funds reported $16.7M of Pasithea Therapeutics stock for Q4 2025, up 3,680% quarter-over-quarter.
  • 12 funds opened new Pasithea Therapeutics positions in Q4 2025 and 5 closed out, a net change of +7 holders.
  • The largest Pasithea Therapeutics buyer in Q4 2025 was Adage Capital Partners, an estimated $1.85M added.
  • The largest Pasithea Therapeutics seller in Q4 2025 was Renaissance Technologies, an estimated $22.5K sold.

Based on aggregated 13F filings for Q4 2025.